Business Standard

Monday, December 23, 2024 | 04:05 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Will $3.8 bn-worth HUL-GSK deal profit India unit? What analysts are saying

Shares in Hindustan Unilever rose 4.1 per cent on Monday to a record, while GlaxoSmithKline Consumer Healthcare Ltd. added 2.8 per cent to its highest level since Sept. 21

GlaxoSmithKline, gsk
Premium

GSK’s assets include the popular malt-based drinks Horlicks and Boost

Abhishek Vishnoi | Bloomberg
A plan by Hindustan Unilever Ltd.’s parent to buy GlaxoSmithKline Plc’s Indian consumer business for 3.3 billion euros ($3.8 billion) in cash and shares is positive for the local unit’s earnings, according to analysts, even as the price tag is said to be about $1 billion more than rival Nestle SA’s offer.

Shares in Hindustan Unilever rose 4.1 percent on Monday to a record, while GlaxoSmithKline Consumer Healthcare Ltd. added 2.8 percent to its highest level since Sept. 21. In London, GlaxoSmithKline slumped 7.6 percent, the most in a decade, while Unilever NV was little changed in Amsterdam.

The buyout “is accretive

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in